Latest Work by Zeglis’ Group

Zeglis‘ Lab at Hunter College is fighting colorectal cancer!
Using inverse electron demand Diels–Alder (IEDDA) reaction on 177Lu-labeled Tz radioligand and an immunoconjugate of the huA33 antibody (huA33-TCO) they improved pretargeted radioimmunotherapy (PRIT).
Left: Schematic of Pretargeted radioimmunotherapy (PRIT) based on the Inverse electron demand Diels–Ald (IEDDA) reaction. Right: Longitudinal therapy study. 

Leave a Reply